ReviewZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026
[Germline DDX41 mutations and myelodysplastic neoplasms].
Review in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DDX41 mutations represent one of the most frequent germline mutations in patients with myelodysplastic neoplasms, conferring unique clinical features of age of onset, prognosis, pathogenic mechanisms, and treatment response. This review summarizes the molecular epidemiology and clinical features of germline DDX41-mutated MDS, with a particular focus on recent advances in the "second-hit" model underlying disease pathogenesis. We further review the efficacy of current therapeutic strategies and discuss the applicability and limitations of existing prognostic scoring systems for this unique patient population. This review aims to provide an updated overview of current evidence and to inform risk stratification, clinical management, and long-term care of patients with germline DDX41-mutated MDS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.